HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Coronavirus Screening Test Developed by Johns Hopkins Microbiologists

By HospiMedica International staff writers
Posted on 20 Mar 2020
Image: Coronavirus screening test developed by Johns Hopkins microbiologists (Photo courtesy of John Hopkins University)
Image: Coronavirus screening test developed by Johns Hopkins microbiologists (Photo courtesy of John Hopkins University)
A team of clinical microbiologists from John Hopkins University (Baltimore, MD) have developed an in-house coronavirus screening test that could allow the health system to test about 1,000 people daily. The test would help people to quickly learn if they are infected with COVID-19 and also allow doctors to test people with whom such patients have come in contact.

The test, which analyzes a nasal or oral swab, was used for the first time on March 11 by the microbiologists who performed around 85 tests during the first three days. The team expects to quickly ramp up capacity and test 180 people per day next week and 500 people in the week after that to reach 1,000 tests per day by early April. Currently, the test delivers results in about 24 hours, which the doctors hope to shorten to three hours.

“We will be able to diagnose more cases. This will allow the control of exposure,” said Heba Mostafa, M.B.B.Ch., Ph.D., assistant professor of pathology and director of the molecular virology laboratory at The Johns Hopkins Hospital.

“Testing is very important in terms of identifying cases so epidemiologists can then contact people exposed to individuals who are known to be positive and make recommendations about home isolation and further follow-up,” added Karen Carroll, M.D., professor of pathology and director of the Division of Medical Microbiology at Johns Hopkins.

Related Links:
John Hopkins University

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Adjustable Mobile Barrier
M-458

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more